Actively Recruiting
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
Led by Tongji Hospital · Updated on 2026-02-11
103
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment (Celiac Plexus Block) with standard first-line cancer drugs. Patients in this study will receive the Celiac Plexus Block procedure, which is intended to reduce pain, and will then begin their standard cancer medication regimen. Researchers will observe and compare how well this combined approach works to control pain and the cancer itself, and will monitor for any side effects. Participation in this study involves being followed by the research team for up to 2 years to track health outcomes. The goal is to see if starting cancer treatment together with this specialized pain management technique is more helpful for patients compared to what is already known about the standard treatments alone.
CONDITIONS
Official Title
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with histologically confirmed advanced biliopancreatic cancer (biliary tract or pancreatic cancer)
- Moderate to severe cancer-related abdominal pain with a Numeric Rating Scale score of 4 or higher for more than 1 week
- Planned to receive first-line systemic cancer treatment (such as PD-1/PD-L1 inhibitors with or without chemotherapy/targeted therapy)
- ECOG Performance Status between 0 and 2
- Estimated life expectancy of 3 months or more
You will not qualify if you...
- Previous celiac plexus neurolysis or ablation procedure
- Blood clotting disorders (INR greater than 1.5 or platelet count below 50 x 10⁹/L)
- Severe heart, liver, or kidney failure (Child-Pugh Class C liver disease, eGFR below 30 mL/min, or NYHA Class III-IV heart failure)
- Contraindications to celiac plexus block such as local infection or anatomical differences
- Any other medical conditions that would make participation unsafe as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
Y
Yang Dr. Wu, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here